CXCL10 and neoplasm: These effects were due to the secretion of CXCL10 by gemcitabine-treated MSCs, which led to activation of the CXCL10-CXCR3 axis and subsequently to the activation of the STAT3 signalling pathway in tumour-initiating cells.